Recombinant human Claudin18.2 tumor vaccine and preparation method thereof

A rhhis-tt-claudin18.2, tumor vaccine technology, applied in the field of medicine and biology, can solve the problems of high recurrence rate of surgical resection, strong toxic and side effects of chemotherapy and radiotherapy, and high cost of monoclonal antibody treatment, and achieves easy and safe preparation method. high sex effect

Inactive Publication Date: 2009-11-25
西安杰诺瓦生物科技有限公司
View PDF0 Cites 28 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0026] In summary, the purpose of the present invention is to provide a recombinant human Claudin18.2 tumor vaccine and its preparation method to overcome the high recurrence rate of surgical resection and the The side effects of chemotherapy and radiotherapy are strong, and the cost of monoclonal antibody treatment is high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant human Claudin18.2 tumor vaccine and preparation method thereof
  • Recombinant human Claudin18.2 tumor vaccine and preparation method thereof
  • Recombinant human Claudin18.2 tumor vaccine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0042] In order to understand the present invention more clearly, the present invention will be further described in detail below in conjunction with the embodiments completed by the inventor.

[0043] The present invention will be described in further detail below in conjunction with the accompanying drawings and embodiments.

[0044] 1. The recombinant human Claudin18.2 tumor vaccine (rhHis-TT-Claudin18.2) provided by the present invention has an amino acid sequence of:

[0045] HMKSSQYIKANSKFIGEFDQWSTQDLYNNPVTAVFNYQGLWRSCVRESSGFTECRGYFTLLGLPAMLQAV

[0046] 2. The above-mentioned recombinant human Claudin18.2 tumor vaccine (rhHis-TT-Claudin18.2) preparation method comprises the following steps in turn:

[0047] (1) Cloning of rhHis-TT-Claudin18.2 gene and construction of prokaryotic expression vector:

[0048] According to the gene sequence of the first extracellular region of human Claudin18.2 in GeneBank, the conventional RT-PCR method was used to introduce the EcoRI res...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicinal biotechnology, and in particular relates to a recombinant human Claudin18.2 tumor vaccine and a preparation method thereof. The invention aims to solve the problems of immunotherapy for stomach cancer, pancreatic cancer, esophagus cancer and metastatic and non-metastatic ovarian cancer, such as high after-excision recurrence rate, strong chemo-treatment and radiation treatment toxic side effect and high monoclonal antibody therapy cost. The invention adopts a technical proposal that the recombinant human Claudin18.2 tumor vaccine has a sequence of HMKSSQYIKANSKFIGEFDQWSTQDLYNNPVTAVFNYQGLWRSCVRESSGFTECRGYFTLLGLPAMLQAV. Animal experiments prove that rhClaudin18.2 fusion protein can induce high-titre neutralizing antibody in the bodies of tumor-bearing mice by over 1:10,000; the antibody can be combined with human KATOIII and PANC-1 tumor cells and mouse stomach cancer MFC and pancreatic cancer MPC-83 cells; and the protein serving as a tumor vaccine can suppress the growth of the stomach cancer MFC and pancreatic cancer MPC-83 cells in the bodies of the mice.

Description

1. Technical field [0001] The invention belongs to the field of medical biotechnology, and specifically relates to gene cloning, gene recombination, expression of foreign genes in prokaryotic cells, purification of target proteins, animal immunization experiments, tumor suppression experiments of induced antiserum, and further relates to recombinant human Claudin18 .2 Tumor vaccine and its preparation method. 2. Background technology [0002] For more than 20 years, research results on human tumor immune responses have shown that antigens expressed by tumor cells can cause specific cellular and humoral immune responses, but cases of spontaneous tumor clearance through endogenous immune mechanisms are extremely rare. In 2004, Giorgio Parmiani pointed out that only 12% of patients showed clinical response after treatment in the clinical phase I-II of stage IV melanoma patients treated with peptide-based vaccines. In recent years, in cases of treatment with autologous dendriti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61P35/00C12N15/70C12P21/02C12R1/19
Inventor 张松刘镭
Owner 西安杰诺瓦生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap